Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CareDx, Inc. (CDNA)

CareDx Q3 revenue rises 39% to $139 million; raises 2026 revenue and EBITDA guidance

Positive Impact 4 of 5 guidance Written later

CareDx reported third-quarter 2026 revenue of $139 million, up 39% from a year earlier, and GAAP net income of $19 million, compared with $2 million in the third quarter of 2025. The company raised its full-year 2026 revenue guidance to $520 million to $530 million and its adjusted EBITDA guidance to $90 million to $100 million, which points to higher expected results for shareholders.

Key points

  • Q3 2026 revenue was $139 million, up 39% year-over-year; Testing Services revenue was $119 million, up 65%.
  • GAAP diluted net income per share was $0.35, compared with $0.03 in the third quarter of 2025; net income included an $8.6 million income tax benefit.
  • 2026 revenue guidance raised to $520 million to $530 million, from $490 million to $500 million previously.
  • 2026 adjusted EBITDA guidance raised to $90 million to $100 million, from $66 million to $78 million previously.

The filing

CompanyCareDx, Inc. (CDNA)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:02 PM ET
Accession number0001217234-26-000059

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.